Article
Gastroenterology & Hepatology
Rachel Levy, Manar Matar, Maya Zvuloni, Raanan Shamir, Amit Assa
Summary: TC response to adjustment of anti-TNFa treatment can be predicted for adalimumab but not for infliximab. Decreasing interval for adalimumab results in increased TC, while increasing interval for adalimumab and dose increase for infliximab both lead to decreased TC.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2023)
Article
Pharmacology & Pharmacy
Jill L. Kinzer, Troy A. Halseth, Jukyung Kang, Sang Yeop Kim, Preethi Kumaran, Michael Ford, Sergei Saveliev, St John Skilton, Anna Schwendeman
Summary: FDA-approved anti-TNF alpha biopharmaceuticals have been successful in treating autoimmune diseases, but there are product-specific differences in patient outcomes, possibly due to structural and functional differences. In this study, we compared the structural and functional differences among three anti-TNF alpha mAbs (Humira (R), Remicade (R), and Simponi Aria (R)) to understand their implications on efficacy.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Gastroenterology & Hepatology
Nicholas A. Kennedy, James R. Goodhand, Claire Bewshea, Rachel Nice, Desmond Chee, Simeng Lin, Neil Chanchlani, Jeffrey Butterworth, Rachel Cooney, Nicholas M. Croft, Ailsa L. Hart, Peter M. Irving, Klaartje B. Kok, Christopher A. Lamb, Jimmy K. Limdi, Jonathan Macdonald, Dermot Pb McGovern, Shameer J. Mehta, Charles D. Murray, Kamal Patel, Richard C. G. Pollok, Timothy Raine, Richard K. Russell, Christian P. Selinger, Philip J. Smith, Jack Bowden, Timothy J. McDonald, Charlie W. Lees, Shaji Sebastian, Nicholas Powell, Tariq Ahmad
Summary: The study found that patients with inflammatory bowel disease treated with infliximab had attenuated serological responses to SARS-CoV-2 infection. Additionally, the serological response to SARS-CoV-2 infection in the infliximab-treated group was further blunted by concomitant use of immunomodulators.
Article
Gastroenterology & Hepatology
Alexa N. Sasson, Ashwin N. Ananthakrishnan
Summary: This study suggests that patients with high titers of anti-drug antibodies to infliximab are as likely to respond to adalimumab therapy as those with low titers, indicating that high titers of antibodies are not predictive of treatment failure.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Immunology
Shin Ju Oh, Young Nam Kwon, Chang Kyun Lee, Jin San Lee
Summary: This is the first report of infliximab-associated anti-NMDAR encephalitis in Crohn's disease, highlighting the need for clinicians to recognize the possibility of a paradoxical autoimmune response occurring with novel biological therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Xiao-Wen Huang, Huan-Xin Zheng, Meng-Lei Wang, Wan-Mei He, Mei-Xin Feng, Kang Zeng, Li Li
Summary: This retrospective study describes the successful use of the anti-TNF-alpha agent adalimumab in three cases of refractory livedoid vasculopathy and provides clinical evidence of its ability to improve skin lesions and relieve pain.
Article
Gastroenterology & Hepatology
Haggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, Sigal Pressman, Amjad Mousa, Edmond Sabo, Matti Waterman, Bella Ungar, Shomron Ben-Horin, Yehuda Chowers
Summary: Therapeutic drug monitoring is essential when guiding anti-TNF therapy for inflammatory bowel disease. This study found differences in tissue dynamics between infliximab and adalimumab, with SDL correlating with tissue free drug levels. Understanding these interactions could lead to improved therapeutic strategies in the future.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Immunology
Fabien Francois, Loubna Naimi, Xavier Roblin, Anne-Emmanuelle Berger, Stephane Paul
Summary: The study evaluated the LISA-TRACKER assays for monitoring ABP501 and anti-ABP501 antibodies in human serum, showing that the assays are reliable and accurate. The results demonstrated the validity and consistency of using LISA-TRACKER for monitoring patients treated with ABP501.
Article
Gastroenterology & Hepatology
Rachel Nice, Neil Chanchlani, Harry Green, Claire Bewshea, Tariq Ahmad, James R. Goodhand, Timothy J. McDonald, Mandy H. Perry, Nicholas A. Kennedy
Summary: This study validates the positivity thresholds for drug-tolerant anti-infliximab and -adalimumab antibody assays, and finds that low-concentration anti-drug antibodies were associated with lower drug levels and treatment failure, particularly for adalimumab. It highlights the importance of deriving antibody positivity thresholds for accurate detection and treatment outcomes.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Pharmacology & Pharmacy
Zvonimir Petric, Joao Goncalves, Paulo Paixao
Summary: Monoclonal antibodies have revolutionized the treatment of chronic inflammatory diseases, but they face challenges related to their immunogenicity, effectiveness, and safety. Biosimilars have emerged as a cost-effective alternative and have been shown to be as safe and effective as the originator drugs in treating IBD patients.
Article
Biochemistry & Molecular Biology
Anne Emmanuelle Berger, Aude Gleizes, Louis Waeckel, Xavier Roblin, Roman Krzysiek, Salima Hacein-Bey-Abina, Alessandra Soriano, Stephane Paul
Summary: This study evaluated the application performance of a new chemiluminescent instrument (i-TRACK10(R)) in clinical decision-making. The results showed satisfactory intra- and inter-run performances of i-TRACK10(R) and generally comparable results to manual or automated ELISA. However, due to differences in anti-drug antibodies, it is recommended to use the same assay in the long-term follow-up of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Shaden Mahmmod, Johannes P. D. Schultheiss, Ad A. van Bodegraven, Gerard Dijkstra, Lennard P. L. Gilissen, Frank Hoentjen, Maurice W. M. D. Lutgens, Nofel Mahmmod, Andrea E. Van der Meulen-de Jong, Lisa J. T. Smits, Adriaan C. I. T. L. Tan, Bas Oldenburg, Herma H. Fidder
Summary: In a retrospective multicenter cohort study, about 9.9% of IBD patients who were switched from originator infliximab to biosimilar CT-P13 experienced reverse switching, predominantly due to biosimilar-attributed adverse effects. Some patients showed symptom improvement after reverse switching, with a good response seen in those who had lost response to CT-P13.
INFLAMMATORY BOWEL DISEASES
(2021)
Review
Pediatrics
Kaija-Leena Kolho
Summary: The prevalence of pediatric-onset inflammatory bowel disease (IBD) has been increasing in recent decades, leading to a rise in patients with moderate to severe disease subtype treated with TNF alpha antagonists. While most pediatric patients initially respond to these drugs, dose escalation may be required during the first year of therapy. Due to limited data on therapeutic drug monitoring during therapy with the TNF alpha-blocker adalimumab in pediatric patients, this review focuses on the literature on therapeutic drug monitoring of infliximab and its potential to guide management.
FRONTIERS IN PEDIATRICS
(2021)
Review
Gastroenterology & Hepatology
Edo H. J. Savelkoul, Pepijn W. A. Thomas, Lauranne A. A. P. Derikx, Nathan den Broeder, Tessa E. H. Romkens, Frank Hoentjen
Summary: Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, with an annual rate of 10% for infliximab and 13% for adalimumab. Dose escalation rates were higher than loss of response, with 72% and 52% regaining clinical benefit for infliximab and adalimumab, respectively. Uniform definitions are needed for more robust evaluations.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Pharmacology & Pharmacy
Beatriz Orts, Ana Gutierrez, Lucia Madero, Laura Sempere, Ruben Frances, Pedro Zapater
Summary: There are differences in the immunological profile and clinical evolution of patients with Crohn's disease according to the anti-TNF dose and serum trough levels.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Tessa Straatmijer, Vince B. C. Biemans, Marijn Visschedijk, Frank Hoentjen, Annemarie de Vries, Adriaan A. van Bodegraven, Alexander Bodelier, Nanne K. H. de Boer, Gerard Dijkstra, Noortje Festen, Carmen Horjus, Jeroen M. Jansen, Bindia Jharap, Wout Mares, Fiona D. M. van Schaik, Cyriel Ponsioen, Tessa Romkens, Nidhi Srivastava, Michael M. P. J. A. van der Voorn, Rachel West, Janneke van der Woude, Marije D. J. Wolvers, Marieke Pierik, Andrea E. van der Meulen-de Jong, Marjolijn Duijvestein
Summary: This study compared the effectiveness and safety of vedolizumab and tofacitinib in anti-TNF-exposed patients with UC. The results showed that tofacitinib was associated with superior effectiveness outcomes compared with vedolizumab, along with comparable safety outcomes.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Lei Liu, Mehdi Sadaghian Sadabad, Giorgio Gabarrini, Paola Lisotto, Julius Z. H. von Martels, Hannah R. R. Wardill, Gerard Dijkstra, Robert E. Steinert, Hermie J. M. Harmsen
Summary: This study investigated the effects of riboflavin supplementation on gut microbiota, short-chain fatty acids, and gut hormones. The results revealed an increase in butyrate production and enhancement of microbial interaction network after riboflavin intervention. However, riboflavin supplementation did not impact the abundance of F. prausnitzii. Additionally, supplementation with 100 mg/d of riboflavin showed a trend of increased plasma insulin and GLP-1 levels.
ANTIOXIDANTS & REDOX SIGNALING
(2023)
Article
Gastroenterology & Hepatology
Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Lowenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. Van der Meulen-de Jong, Marjolijn Duijvestein
Summary: The aim of this study was to evaluate the effectiveness and safety of 24 months of tofacitinib use in patients with ulcerative colitis in the Netherlands. The results showed that 31.8% of patients achieved corticosteroid-free clinical remission after 24 months of tofacitinib treatment. The main side effects were skin reactions and headaches.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Jeanine H. C. Arkenbosch, Evelien M. J. Beelen, Gerard Dijkstra, Marielle Romberg-Camps, Marjolijn Duijvestein, Frank Hoentjen, Sander van der Marel, P. W. Jeroen Maljaars, Sita Jansen, Nanne K. H. de Boer, Rachel L. West, Carmen S. Horjus, Laurents P. S. Stassen, Fiona D. M. van Schaik, Oddeke van Ruler, Bindia J. H. Jharap, Marijn Visschedijk, Alfred Janssen, Nicole S. Erler, Michail Doukas, Ariadne H. A. G. Ooms, Gursah Kats-Ugurlu, C. Janneke van der Woude, Annemarie C. de Vries
Summary: This study aimed to evaluate the effectiveness of a clinical management algorithm in preventing recurrence after ileocolonic resection in Crohn's disease and determine the predictive value of clinical and histological risk factors. The results showed that prophylactic medication can effectively reduce endoscopic recurrence in both low-risk and high-risk patients. Clinical risk stratification has a certain predictive value in predicting patient recurrence but further improvements are needed.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Psychology, Clinical
Quirine M. Bredero, Joke Fleer, Ans Smink, Greetje Kuiken, Joke Potjewijd, Marleen Laroy, Marijn C. Visschedijk, Maurice Russel, Mark van der Lugt, Maarten A. C. Meijssen, Egbert Jan van der Wouden, Gerard Dijkstra, Maya J. Schroevers
Summary: This study aimed to examine the efficacy of Mindfulness-Based Cognitive Therapy (MBCT) in reducing fatigue symptoms in patients with inflammatory bowel disease (IBD) in remission. The results showed that an 8-week MBCT group program effectively reduced the subjective experience of fatigue in patients, but had no significant effects on other fatigue aspects or secondary outcomes.
Letter
Gastroenterology & Hepatology
Sem Geertsema, Harry van Goor, Gerard Dijkstra, Klaas Nico Faber, Arno R. Bourgonje
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Urology & Nephrology
Tim J. Knobbe, Daan Kremer, Rianne M. Douwes, Michele F. Eisenga, Antonio W. Gomes-Neto, Coby Annema, J. Casper Swarte, Frank Klont, Gerjan Navis, Stefan P. Berger, Stephan J. L. Bakker
Summary: Prior studies have shown that the use of proton pump inhibitors (PPIs) can negatively impact gut microbiota and the absorption of micronutrients, such as iron and magnesium. This study aims to investigate the association between PPI use and fatigue and health-related quality of life (HRQoL) in kidney transplant recipients.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2023)
Article
Gastroenterology & Hepatology
Adrianus. M. van Der Holst, Antonius T. Otten, Elise M. Meima-van Praag, Alexander R. P. K. M. van Renterghem, Arno R. Bourgonje, Ellen S. van Loo, Gerard Dijkstra, Christianne J. Buskens, Laurents P. S. Stassen
Summary: Creation of a diverting stoma in patients with Crohn's disease may counteract luminal inflammation. This study aimed to evaluate the long-term effects of a diverting stoma on the disease course. Findings suggest that a diverting stoma could be an alternative in specific populations of patients with luminal colonic CD, especially in the absence of proctitis.
COLORECTAL DISEASE
(2023)
Article
Gastroenterology & Hepatology
Ashkan Rezazadeh Ardabili, Dirk van Esser, Dion Wintjens, Mia Cilissen, Debbie Deben, Zlatan Mujagic, Fritzi Russ, Laurents Stassen, Adriaan A. Van Bodegraven, Dennis Wong, Bjorn Winkens, Daisy Jonkers, Marielle Romberg-Camps, Marie J. Pierik
Summary: A remote monitoring tool, called the PRIQ, has been developed and validated to assess infections in IBD patients, enabling personalized medicine based on adequate benefit-risk assessments.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Pharmacology & Pharmacy
Merve Sivridas, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Romkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, Luc J. J. Derijks
Summary: The aim of this study was to determine the association between vedolizumab (VDZ) trough concentration and clinical and biochemical remission in the maintenance phase. The results showed no statistically significant correlation between VDZ concentration and clinical remission in all patient groups. However, patients in biochemical remission had higher VDZ trough concentrations. Therefore, there is an association between VDZ concentration and biochemical remission, but not with clinical remission.
Editorial Material
Gastroenterology & Hepatology
Ashkan Rezazadeh Ardabili, Adriaan A. Van Bodegraven
Summary: This article is linked to the paper by Everhov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
L. M. Janssen, A. Rezazadeh Ardabili, M. J. L. Romberg-Camps, B. Winkens, R. J. van den Broek, J. Hulst, H. J. A. Verwijs, D. Keszthelyi, D. M. A. E. Jonkers, A. A. van Bodegraven, M. J. Pierik, Z. Mujagic
Summary: Abdominal pain is common in patients with IBD in remission and is associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Antonius T. Otten, Gerard Dijkstra, Marijn C. Visschedijk, Arno R. Bourgonje
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Debbie S. Deben, Luc J. J. Derijks, Bianca J. C. van den Bosch, Rob H. Creemers, Annick van Nunen, Adriaan A. van Bodegraven, Dennis R. Wong
Summary: This study aimed to evaluate the risks and opportunities of using tioguanine in inflammatory bowel disease (IBD) patients with abnormal TPMT metabolism and proposed preventative measures. The findings showed that a reduced dosage of tioguanine with strict monitoring was a safe and effective treatment option for IBD patients with dysfunctional TPMT.
Article
Gastroenterology & Hepatology
Michiel Thomas Jan Bak, Oddeke van Ruler, Laurents Stassen, Marit Ruiterkamp, Jeanine Hubertina Catharina Arkenbosch, Gerard Dijkstra, Maria Johanna Elisabeth Campmans-Kuijpers, Nico Leonard Ulrich van Meeteren, Bart Chateau Bongers, Marielle Romberg-Camps, Sander van der Marel, Frank Hoentjen, Koen Willem van Dongen, Rachel West, Janneke van der Woude, Annemarie Charlotte de Vries
Summary: This study evaluated the current use of preoperative screening and prehabilitation strategies prior to elective ileocolic resection in patients with Crohn's disease. The results showed that preoperative nutritional status screening was only performed in 56% of patients, and 46% of them were found to have malnutrition. Active smoking and alcohol consumption were reported in 20% and 28% respectively, but none of these patients were referred for a cessation program.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2023)